<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944734</url>
  </required_header>
  <id_info>
    <org_study_id>SP-AC-002</org_study_id>
    <nct_id>NCT02944734</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Poong Pharmaceutical Co. Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the optimal dose of fixed-dose combination of&#xD;
      candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the&#xD;
      combination therapy compared to each of the monotherapy in patients with essential&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change mean sitting Diastolic Blood Pressure (msDBP) at week 8 compared to baseline</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change mean sitting Diastolic Blood Pressure (msDBP) at week 4 compared to baseline</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change mean sitting Systolic Blood Pressure (msSBP) at week 4 and 8 compared to baseline</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving treatment goal at week 4 and 8: &lt; 140/90 mmHg</measure>
    <time_frame>Week 4 and 8</time_frame>
    <description>Joint National Committee VII Guideline Treatment goal: &lt; 140/90 mmHg (&lt; 130/80 mmHg, diabetic or chronic renal failure patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Response rate at week 4 and 8: msSBP reduction ≥ 20 mmHg and msDBP reduction ≥ 10 mmHg</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan Cilexetil (CC) 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil 8mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil 16mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine(AML) 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 8mg / AML 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 8mg / AML 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 16mg / AML 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 16mg / AML 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil 8mg</intervention_name>
    <description>Candesartan Cilexetil 8mg Daily oral administration for 8 weeks</description>
    <arm_group_label>CC 8mg / AML 10mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 5mg</arm_group_label>
    <arm_group_label>Candesartan Cilexetil (CC) 8mg</arm_group_label>
    <other_name>Atacand 8mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil 16mg</intervention_name>
    <description>Candesartan Cilexetil 16mg Daily oral administration for 8 weeks</description>
    <arm_group_label>CC 16mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 10mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 5mg</arm_group_label>
    <other_name>Atacand 16mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>Amlodipine 5mg Daily oral administration for 8 weeks</description>
    <arm_group_label>Amlodipine(AML) 5mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 5mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 5mg</arm_group_label>
    <other_name>Norvasc 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg</intervention_name>
    <description>Amlodipine 10mg Daily oral administration for 8 weeks</description>
    <arm_group_label>AML 10mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 10mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 10mg</arm_group_label>
    <other_name>Norvasc 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients greater than or equal to 19 years of age&#xD;
&#xD;
          2. Subject who was diagnosed with essential hypertension or after administer the&#xD;
             antihypertensive drug (Subject who may temporarily suspend antihypertensive treatment&#xD;
             based on doctor's decision)&#xD;
&#xD;
          3. Subject who have voluntarily agreed to participate in the trial and signed the written&#xD;
             informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with severe hypertension (in a selected arm with msSBP ≥ 200 mmHg or msDBP ≥&#xD;
             115 mmHg) during the Screening and Randomized Trial.&#xD;
&#xD;
          2. Subject with difference of the blood pressure of over 20 mmHg for SBP or 10 mmHg for&#xD;
             diastolic blood pressure (DSP) between three consecutive measurements in a selected&#xD;
             arm during the screening visit&#xD;
&#xD;
          3. Secondary hypertension (such as, coarctation of the aorta, primary hyperaldosteronism,&#xD;
             renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease,&#xD;
             etc.)&#xD;
&#xD;
          4. Symptomatic orthostatic hypotension&#xD;
&#xD;
          5. Severe heart failure( New York Heart Association(NYHA) Class III/IV)&#xD;
&#xD;
          6. Subject with acute coronary syndrome(myocardial infarction or unstable angina),&#xD;
             peripheral vascular disease within the past 6 months&#xD;
&#xD;
          7. History of switching to another Antiarrhythmic drugs(not including electrolyte&#xD;
             correction), or received Cardioversion or ICU treatment within the past 6 months&#xD;
&#xD;
          8. Type 1 diabetes mellitus or Uncontrolled Type 2 diabetes mellitus (HbA1c &gt; 9.0%)&#xD;
&#xD;
          9. Subject with Haemodynamic disturbance, heart valve disease with structural defects&#xD;
&#xD;
         10. Severe cerebrovascular disease (stroke, cerebral infarction, or cerebral hemorrhage,&#xD;
             etc. within the past 6 months)&#xD;
&#xD;
         11. Severe eye disease (retinal hemorrhage, visual impairment, retinal microaneurysm, etc.&#xD;
             within the past 6 months)&#xD;
&#xD;
         12. Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)&#xD;
&#xD;
         13. Chronic inflammatory disease requiring continuous anti-inflammatory treatment&#xD;
&#xD;
         14. Clinically significant Renal or liver impairment, or laboratory abnormalities such as&#xD;
             Ccr: below 30ml/min or Aspartate Aminotransferase (AST) or Alanine Aminotransferase&#xD;
             (ALT) &gt; 3 x Upper Limit Normal (ULN)&#xD;
&#xD;
         15. Hypokalaemia(Serum potassium &lt; 3.5 mmol/L) or hyperkalaemia(Serum potassium &gt; 5.5&#xD;
             mmol/L)&#xD;
&#xD;
         16. Subject with gastrointestinal disease(such as Crohn's disease, gastric ulcer, acute or&#xD;
             chronic pancreatitis) or history of gastrointestinal surgery(not including&#xD;
             appendectomy or hernia surgery) that might significantly alter the absorption of the&#xD;
             drug&#xD;
&#xD;
         17. history of allergy or hypersensitivity to Angiotensin II Receptor&#xD;
             Blockers(Candesartan) or Calcium Channel Blocker(amlodipine)&#xD;
&#xD;
         18. Subject with heredity defects such as galactose intolerance, Lapp lactose deficiency,&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
         19. Subject requiring concomitant use of other antihypertensive or contraindicated drugs(&#xD;
             Tizanidine, dolasetron, Itraconazole, potassium, potassium-sparing diuretics, etc.)&#xD;
             during the clinical trial&#xD;
&#xD;
         20. history of malignant tumors within the past 5 years&#xD;
&#xD;
         21. history of alcohol or drug abuse&#xD;
&#xD;
         22. Pregnant women and lactating mothers&#xD;
&#xD;
         23. Women who is planning to be pregnant during or 2 months after the study, or women or&#xD;
             men who are not using medically acceptable methods of contraception *&#xD;
&#xD;
             * progestin oral or implant contraceptive, intra-uterine device, condom, partner with&#xD;
             surgical sterilization, etc.&#xD;
&#xD;
         24. Use of other investigational products within the past 1 month&#xD;
&#xD;
         25. Subject who are judged by the investigator unsuitable to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong-Jin Kim</last_name>
    <role>Study Director</role>
    <affiliation>KyungHee University Hospital at Gangdong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Korea Bucheon St. Mary's Hospital</name>
      <address>
        <city>Wonmi-gu</city>
        <state>Bucheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busanjin-gu</city>
        <state>Busan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Joong-gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Joong-gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Nam- gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Ilsandong-gu</city>
        <state>Goyang-si, Gyeoggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Dong-Gu</city>
        <state>Gwangju</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Uijeongbu St. Mary's hospital</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeoggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Namdong-gu</city>
        <state>Incheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Carollo General Hospital</name>
      <address>
        <city>Suncheon-si</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea St. Paul's Hospital</name>
      <address>
        <city>Dongdaemun-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Dongdaemun-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Gangdong-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Gangdong-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VHS( Veterans Medical Service) Medical Center</name>
      <address>
        <city>Gangdong-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Gwangjin-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongro-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seocho-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seongbuk-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Yeouido St. Mary's Hospital</name>
      <address>
        <city>Yeongdeungpo-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Dong-gu</city>
        <state>Ulsan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Candesartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Antihypertensive Agents</keyword>
  <keyword>Vasodilator Agents</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <keyword>Angiotensin Receptor Antagonists</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

